Coya Therapeutics

COYA

Valor de mercado US$ 100 mi

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced plans to initiate an open-label extension (OLE) of the Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS).Coya plans to initiate the OLE in response to requests from ALSTARS inves.

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced the company will be participating in a panel discussion at Chardan's 10th Annual Healthcare Conference taking place on October 20 in New York.Panel Details:Title: Targeting Neurodegenerative & Neuromuscular Disease: ALS, DMD, Alzheimer's &.

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced full enrollment of the planned 120 participants in the Company's Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, Coya's combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the potential treatment of amyotrophic lateral scle.

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced that the 100th patient has been enrolled in the Company's ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, Coya's combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the treatment of amyotrophic lateral sclerosis (AL.

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the publication of preclinical results for COYA 303 in the International Journal of Molecular Sciences. The article was published as part of the Special Issue, “The Roles of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Health and Disease,” which highlights the expanding therapeutic applic.

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update. “During the second quarter, we made notable progress advancing our lead program, COYA 302,” said Arun Swaminathan, Ph.D., Chief Executive Officer of Coya. “E.

Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing ALSTARS trial, outlining its design and approach to targeting neuroinflammation, at the European Network to Cure ALS (ENCALS) Meeting 2026 which will take place June 24–26, 2026, in Madrid, S.

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced it will host a live webinar on June 24, 2026 at 4 p.m. ET / 1 p.m. PT. Titled ‘Beyond the Hit: How Repetitive Head Trauma, Inflammation, and Neurodegenerative Disease Intersect', the webinar will explore the relationship between repetitive he.

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the initiation of the blinded extension phase of the ALSTARS Trial (ClinicalTrials.gov Identifier: NCT07161999). Patients who complete the 24-week placebo-controlled double-blind phase enter the blinded extension phase of the study and continue on their regimen from the first phase; placebo patients a.